These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

88 related articles for article (PubMed ID: 6394185)

  • 1. Pseudoprimary aldosteronism from the topical application of 9-alpha-fluorprednisolone to the skin.
    Montoliu J; Botey A; Trilla A; Revert L
    Clin Nephrol; 1984 Nov; 22(5):262-6. PubMed ID: 6394185
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Hypermineralcorticism syndrome secondary to topical application of 9-alpha-fluoroprednisolone (author's transl)].
    Vasconez F; Pérez-Garcia R; Olivas E; Bolívar JE; Valderrábano F
    Med Clin (Barc); 1980 Dec; 75(10):430-4. PubMed ID: 7464329
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pseudoprimary hyperaldosteronism from topical application of 9-alpha-fluorprednisolone on the skin.
    Brognoli M; Doregatti C; Roncali M; Orlandini G
    Clin Nephrol; 1985 Dec; 24(6):315-6. PubMed ID: 4075602
    [No Abstract]   [Full Text] [Related]  

  • 4. Normokalemic hyperaldosteronism in patients with resistant hypertension.
    Benchetrit S; Bernheim J; Podjarny E
    Isr Med Assoc J; 2002 Jan; 4(1):17-20. PubMed ID: 11802302
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [High prevalence of undiagnosed primary hyperaldosteronism among patients with essential hypertension].
    Mosso L; Fardella C; Montero J; Rojas P; Sánchez O; Rojas V; Rojas A; Huete A; Soto J; Foradori A
    Rev Med Chil; 1999 Jul; 127(7):800-6. PubMed ID: 10668287
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Excess mineralocorticoid syndrome secondary to nasal sprays containing 9 alpha-fluoroprednisolone].
    Foresti V; Parisio E; Ricci G
    Minerva Med; 1987 Sep; 78(17):1305-11. PubMed ID: 2444906
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Hypopotassemic myopathy caused by topical administration of 9 alpha fluoroprednisolone].
    Molins A; Alvarez-Sabín J; Montalbán J; Molero J; Alegre J; Codina A
    Neurologia; 1987; 2(5):244-6. PubMed ID: 3274232
    [No Abstract]   [Full Text] [Related]  

  • 8. Factitious hypertension with mineralocorticoid excess in an infant.
    De Stefano P; Bongo IG; Borgna-Pignatti C; Severi F
    Helv Paediatr Acta; 1983 May; 38(2):185-9. PubMed ID: 6874387
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Hypertension and hypokalemia caused by a nasal spray containing fluorprednisolone acetate].
    Maiorano G; Loiacono N; Di Bello V; Contursi V; Castelnuovo F; Albano O
    Boll Soc Ital Cardiol; 1981; 26(5):465-71. PubMed ID: 7340877
    [No Abstract]   [Full Text] [Related]  

  • 10. Primary aldosteronism: renaissance of a syndrome.
    Young WF
    Clin Endocrinol (Oxf); 2007 May; 66(5):607-18. PubMed ID: 17492946
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pseudohyperaldosteronism due to application of an antihemorrhoid cream.
    Marin F; González Quintela A; Moya M; Suárez E; de Zárraga M
    Nephron; 1989; 52(3):281-2. PubMed ID: 2739869
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Primary aldosteronism: A common and curable form of hypertension.
    Young WF
    Cardiol Rev; 1999; 7(4):207-14. PubMed ID: 10423672
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 'Essential' hypertension with hypokalemia. Caused by aldosterone-secreting adrenal adenoma.
    Burke M; Papo J; Stavorovsky M; Almog C
    Postgrad Med; 1984 Aug; 76(2):173, 176-8. PubMed ID: 6462970
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A case of primary aldosteronism due to unilateral adrenal hyperplasia.
    Katayama Y; Takata N; Tamura T; Yamamoto A; Hirata F; Yasuda H; Matsukuma S; Daido Y; Sasano H
    Hypertens Res; 2005 Apr; 28(4):379-84. PubMed ID: 16138569
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Arterial hypertension secondary to the application of 9-alpha-fluoroprednisolone ointments].
    Arnal JM; Moneo MI; Loris C
    An Esp Pediatr; 1987 Jan; 26(1):65-6. PubMed ID: 3826948
    [No Abstract]   [Full Text] [Related]  

  • 16. Selection of patients for surgery for primary aldosteronism.
    Plouin PF; Rossignol P; Amar L
    Clin Exp Pharmacol Physiol; 2008 Apr; 35(4):522-5. PubMed ID: 18307754
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical and biochemical characteristics of normotensive patients with primary aldosteronism: a comparison with hypertensive cases.
    Médeau V; Moreau F; Trinquart L; Clemessy M; Wémeau JL; Vantyghem MC; Plouin PF; Reznik Y
    Clin Endocrinol (Oxf); 2008 Jul; 69(1):20-8. PubMed ID: 18284637
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Primary aldosteronism presented with intracranial hemorrhage].
    Nakagawa A; Su CC; Saito K; Yamashita Y; Shirane R; Yoshimoto T
    No Shinkei Geka; 2001 Oct; 29(10):973-7. PubMed ID: 11681014
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The diagnosis of primary aldosteronism and separation of two major subtypes.
    Weinberger MH; Fineberg NS
    Arch Intern Med; 1993 Sep; 153(18):2125-9. PubMed ID: 8379804
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Hypokalemic myopathy caused by fluoroprednisolone in a nasal spray. Observations 2 cases].
    Cantello R; Bergamini L; Delsedime M; Durelli L; Troni W; Gilli M; Cocito D
    Minerva Med; 1983 Jun; 74(25):1463-7. PubMed ID: 6856155
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.